

Tissue Glucocorticoid Metabolism in Adrenal Insufficiency: A Prospective Study of Dual-release Hydrocortisone Therapy

Rosemary A. Dineen,¹ Julie Martin-Grace,¹ Khalid Mohamed Saeed Ahmed,² Angela E. Taylor,³ Fozia Shaheen,³ Lina Schiffer,³ Lorna C. Gilligan,³ Gareth G. Lavery,³ Isolda Frizelle,² Anjuli Gunness,² Aoife Garrahy,¹ Anne Marie Hannon,¹ Paal Methlie,⁴ Sverre Husebye Eystein,⁴ Paul M. Stewart,⁵ Jeremy W. Tomlinson,⁶ James M. Hawley,⁷ Brian G. Keevil,⁷ Michael W. O'Reilly,¹ Diarmuid Smith,¹ John McDermott,⁸ Marie-Louise Healy,⁹ Amar Agha,¹ Agnieszka Pazderska,⁹ James Gibney,² Lucy-Ann Behan,² Chris J. Thompson,¹ Wiebke Arlt,^{3,10} and Mark Sherlock¹

¹Academic Department of Endocrinology, Beaumont Hospital/Royal College of Surgeons in Ireland, Dublin, D09 YD60, Ireland

²Robert Graves Institute of Endocrinology, Tallaght University Hospital, Dublin, D24 TP66, Ireland

³Institute of Metabolism and Systems Research, University of Birmingham, Birmingham B15 2TT, UK

⁴Department of Clinical Science, University of Bergen, 5021 Bergen, Norway

⁵Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK

⁶Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, Churchill Hospital, University of Oxford, Oxford OX3 7LE, UK

⁷Department of Clinical Biochemistry, University Hospital of South Manchester, Manchester Academic Health Science Centre, The University of Manchester, Manchester M23 9LT, UK

⁸Department of Endocrinology, Connolly Hospital, Dublin, D15 X40D, Ireland

⁹Department of Endocrinology, St James Hospital, Dublin, D08 K0Y5, Ireland

¹⁰Medical Research Council London, Institute of Medical Sciences, London W12 0NN, UK

Correspondence: Mark Sherlock, Academic Department of Endocrinology, Beaumont Hospital and the Royal College of Surgeons in Ireland, Dublin, D09 YD60, Ireland. Email: marksherlock@rcsi.ie.

Abstract

Background: Patients with adrenal insufficiency (AI) require life-long glucocorticoid (GC) replacement therapy. Within tissues, cortisol (F) availability is under the control of the isozymes of 11 β -hydroxysteroid dehydrogenase (11 β -HSD). We hypothesize that corticosteroid metabolism is altered in patients with AI because of the nonphysiological pattern of current immediate release hydrocortisone (IR-HC) replacement therapy. The use of a once-daily dual-release hydrocortisone (DR-HC) preparation, (Plenadren®), offers a more physiological cortisol profile and may alter corticosteroid metabolism *in vivo*.

Study Design and Methods: Prospective crossover study assessing the impact of 12 weeks of DR-HC on systemic GC metabolism (urinary steroid metabolome profiling), cortisol activation in the liver (cortisone acetate challenge test), and subcutaneous adipose tissue (microdialysis, biopsy for gene expression analysis) in 51 patients with AI (primary and secondary) in comparison to IR-HC treatment and age- and BMI-matched controls.

Results: Patients with AI receiving IR-HC had a higher median 24-hour urinary excretion of cortisol compared with healthy controls (72.1 μ g/24 hours [IQR 43.6–124.2] vs 51.9 μ g/24 hours [35.5–72.3], $P = .02$), with lower global activity of 11 β -HSD2 and higher 5 α -reductase activity. Following the switch from IR-HC to DR-HC therapy, there was a significant reduction in urinary cortisol and total GC metabolite excretion, which was most significant in the evening. There was an increase in 11 β -HSD2 activity. Hepatic 11 β -HSD1 activity was not significantly altered after switching to DR-HC, but there was a significant reduction in the expression and activity of 11 β -HSD1 in subcutaneous adipose tissue.

Conclusion: Using comprehensive *in vivo* techniques, we have demonstrated abnormalities in corticosteroid metabolism in patients with primary and secondary AI receiving IR-HC. This dysregulation of pre-receptor glucocorticoid metabolism results in enhanced glucocorticoid activation in adipose tissue, which was ameliorated by treatment with DR-HC.

Key Words: cortisol, adrenal insufficiency, 11 β -hydroxysteroid dehydrogenase, metabolism

Abbreviations: 5 α R, 5 α -reductase; 5 α -THF, 5 α tetrahydrocortisol; 11 β -HSD, 11 β -hydroxysteroid dehydrogenase; AI, adrenal insufficiency; BMI, body mass index; DR-HC, dual-release hydrocortisone; GC, glucocorticoid; GR, glucocorticoid receptor; IQR, interquartile range; IR-HC, immediate release hydrocortisone; LC-MS/MS, liquid chromatography-tandem mass spectrometry; PAI, primary adrenal insufficiency; QoL, quality of life; SAI, secondary adrenal insufficiency.

Patients with adrenal insufficiency (AI) receiving essential glucocorticoid (GC) replacement therapy continue to have increased morbidity and premature mortality (1-4) with the exact mechanisms underpinning this increased mortality not fully elucidated. Patients with AI receiving GC replacement exhibit adverse metabolic and body composition profiles, including a propensity to central obesity and visceral fat disposition compared with control populations with similar body mass index (BMI) (5-8). Standard GC therapy with immediate release hydrocortisone (IR-HC) is unable to accurately replicate the physiological circadian cortisol rhythm, and together with the uncertainties of glucocorticoid dose adjustment and the absence of reliable biomarkers, patients receiving GC therapy may be over- or-underexposed to cortisol over a 24-hour period.

To mimic the physiological circadian rhythm of endogenous cortisol, novel modified-release hydrocortisone preparations have been developed. The dual-release formulation of hydrocortisone (DR-HC), Plenadren®, has been licensed for use in clinical practice and is taken once daily in the morning. In a prospective crossover study including patients with primary and secondary adrenal insufficiency, we have previously shown favorable metabolic changes following 12 weeks of DR-HC therapy with improvements in blood pressure, weight reduction, and improved quality of life (QoL) (9).

A further confounding issue in patients receiving exogenous GC therapy is the tissue-specific regulation of glucocorticoid action. Although circulating GC concentrations are regulated by the hypothalamic-pituitary-adrenal (HPA) axis, at the tissue level, GC action is also modulated through a series of enzymes, including the isozymes of 11 β -hydroxysteroid dehydrogenases (11 β -HSD). The 2 isozymes of 11 β -HSD interconvert hormonally active cortisol (F) and inactive cortisone (E). 11 β -HSD type 2 inactivates cortisol to cortisone in mineralocorticoid tissues such as the kidney, whereas 11 β -HSD type 1 performs the reverse reaction converting inactive cortisone to active cortisol in key GC metabolic tissues including the liver and adipose tissue (10). Alteration in expression of these 11 β -HSD isozymes in peripheral tissues modifies corticosteroid action. Tissues may thus be exposed to a relative excess of cortisol without any increase in cortisol secretion or circulating plasma cortisol concentrations. Glucocorticoids are also metabolized by the A-ring reductases, 5 α -reductase (5 α R), 5 β -reductase, and 3 α -hydroxysteroid dehydrogenase, to their tetrahydro metabolites. Thus, 5 α -reduction contributes significantly to the metabolism and clearance of GCs (11). Several translational study techniques can be employed in clinical studies to investigate corticosteroid metabolism in vivo including urine steroid metabolite ratios in 24-hour collections (12), tissue-specific biopsies to measure gene expression, and dynamic tests such as cortisol generation profiles (13).

We hypothesize that corticosteroid metabolism is altered in patients with AI because of supraphysiological GC replacement therapy and the nonphysiological pattern of current IR-HC replacement therapy. The use of DR-HC, Plenadren®, may lead to improved markers of steroid metabolism because of the more physiological profile, which may restore normal GC metabolism. With this background, we aimed to perform a detailed prospective, crossover study to first characterize corticosteroid metabolism in patients with primary and secondary adrenal insufficiency and compared with an age-, gender-, and BMI-matched control population at baseline and after 12 weeks of DR-HC therapy.

Methods

Study Design and Population

We performed an investigator-initiated, open-labeled, multi-site, prospective study at two University Hospitals in Ireland (Tallaght University Hospital and Beaumont Hospital). This study could not be blinded or placebo-controlled because of the risk of adrenal crisis in the study population with primary adrenal insufficiency (PAI) and secondary adrenal insufficiency (SAI). The inclusion and exclusion criteria of the study population have been previously published (9). Briefly, eligible patients were male and female patients aged ≥ 18 years, with a diagnosis of AI, either PAI or SAI, who were on immediate-release hydrocortisone replacement therapy, without any adjustment in hormone replacement for at least 3 months before study entry. Control participants were healthy individuals recruited via local advertisement and a diagnosis of adrenal insufficiency was excluded by clinical and biochemical parameters.

The study was approved by the Joint Research Ethics Committee of Tallaght University Hospital/St James's Hospital and the Beaumont Hospital Research Ethics Committee. Written informed consent was obtained from all patients before participation. All patients had an emergency kit and a steroid emergency card and received education regarding the management of an adrenal crisis.

This study was registered with ClinicalTrials.gov as NCT03282487.

Clinical Protocol

After screening for eligibility and obtaining informed consent, study participants attended the research unit in the Department of Endocrinology, Tallaght University Hospital, or the Clinical Research Facility, Beaumont Hospital, after an 8-hour fast on 2 separate occasions, visit 1 and visit 2, for a day of integrated assessments (Fig. 1). On visit 1, patients presented for baseline evaluation on IR-HC therapy. Thereafter, if biochemical investigations were within the normal reference range, patients were switched from IR-HC to the daily dose equivalent of once-daily DR-HC, Plenadren®, per the summary of product characteristics, for 12 weeks. At the end of the intervention treatment period, patients presented for visit 2. Thereafter, patients were switched back to their usual IR-HC regimen because Plenadren was not available in clinical practice in Ireland at the time of the study. Patients were followed up in the outpatient clinic according to the standard surveillance protocol of the clinic. Control participants presented after an overnight fast on a single occasion and underwent the same biochemical investigations except for the adipose tissue biopsy and microdialysis.

At each visit (before and 12 weeks after DR-HC), patients presented at 8 AM, having taken 1 mg of dexamethasone at 11 PM/midnight the night before the visit. A complete physical examination was performed in addition to baseline anthropometric assessment, which included body composition analysis with a bioimpedance body composition analyzer (Tanita BC418 MA for patients recruited in Tallaght University Hospital and Tanita DC360 S for patients in Beaumont Hospital). Baseline blood was drawn for fasting laboratory investigations including routine renal/bone/liver profiles, fasting total cholesterol, high-density lipoprotein- and low-density lipoprotein-cholesterol, triglycerides, hemoglobin A1c, C-reactive protein, and full blood count using in-hospital assays.




Figure 1. Study protocol. Study visit 1 completed on IR-HC and visit 2 completed after 12 weeks of DR-HC. Patients fasted for the duration of the cortisol generation curve. Healthy control participants did not undergo the adipose tissue biopsy. AI, adrenal insufficiency; BIA, bioelectric impedance (BIA); DR-HC, dual-release hydrocortisone; IR-HC, conventional immediate-release hydrocortisone.

Measurement of Corticosteroid Metabolism

Global corticosteroid metabolism

Immediate-release HC results in peaks and troughs in serum cortisol levels over the day (14), which may not be reflected in a 24-hour urine collection because this provides a global assessment of urinary steroid excretion. Therefore, all study participants collected 24-hour urine in 8-hourly intervals, in 3 separate containers (ie, bottle A, urine from 8.00 AM–4.00 PM; bottle B, urine from 4.00 PM–midnight; and bottle C, urine from midnight–8.00 AM). This was performed in the week before visit 1 (on IR-HC), and before visit 2 (12 weeks after DR-HC) but not in the 24 hours when dexamethasone was taken (ie, not the day before each visit) because this would interfere with steroid metabolite excretion. The total urine volume for each 8-hourly collection was recorded and two 20-mL volumes were preserved for storage at -80°C until analysis for quantitative data on the urinary excretion of individual cortisol metabolites could be performed.

Urinary steroid metabolite excretion analysis was carried out by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in the Institute of Metabolism and Systems Research, University of Birmingham, UK, using a Waters Xevo mass spectrometer with Acquity uPLC system, as previously described (15). The systemic relative $5\alpha\text{R}$ activity was assessed by the ratio of 5α -tetrahydrocortisol ($5\alpha\text{-THF}$)/tetrahydrocortisol (THF). The ratio of $(\text{THF} + 5\alpha\text{-THF})/\text{tetrahydrocortisone (THE)}$ was used as a marker of $11\beta\text{-HSD1}$ activity, and the ratio of urinary cortisol:urinary cortisone (urinary F/E) as a reflection of $11\beta\text{-HSD2}$ activity. Total GC metabolite excretion was assessed as the sum of $5\alpha\text{THF} + \text{THF} + \text{THE} + \text{cortols} + \text{cortolones} + \text{cortisol} + \text{cortisone}$. Patients' results were compared with an age-, gender-, and BMI-matched healthy control database established by the Institute of Metabolism and Systems Research.

Hepatic corticosteroid metabolism: cortisol generation curves

After baseline fasting bloods were taken, participants were given 25 mg of oral cortisone acetate. Following this, serial 30-minute serum samples were taken for 240 minutes.

Measuring cortisol generated over time from oral cortisone acetate (in a dexamethasone-suppressed state) results in a curve representing $11\beta\text{-HSD1}$ activity predominantly in the liver (16, 17). The serum samples stood at room temperature for 30 minutes to facilitate clotting before being centrifuged at 3000 rpm for 15 minutes, stored in 1-mL aliquots and at -80°C until analysis. Serum cortisol and cortisone were analyzed by LC-MS/MS as previously described (18). For cortisol, analytical performance characteristics were as previously described (18). For cortisone, inter-assay imprecision was 5.5%, 3.9%, and 3.8% at concentrations of 5.0, 50.0, and 150 nmol/L, respectively. Mean recoveries ranged from -9% to 104% over concentrations of 63 to 500 nmol/L and ion suppression was found to be negligible ($<10\%$). The limit of quantitation was 2.5 nmol/L, and the assay was free from analytical interferences.

Assessment of adipose tissue cortisol metabolism: adipose tissue microdialysis

Adipose microdialysis was carried out, as described by Tomlinson et al (16). After cleaning the skin with iodine solution, a CMA63® microdialysis catheter (CMA Microdialysis, Stockholm) was inserted into the subcutaneous adipose tissue, approximately 10 cm lateral and 5 cm inferior to the umbilicus. As per the serum cortisol generation curves, participants were given 25 mg of oral cortisone acetate (in a dexamethasone-suppressed state) and after a flush sequence ($15\mu\text{L}$ over 5 minutes), microdialysis was performed at a rate of $0.3\mu\text{L}$ per minute, with serial 30-minute microdialysis samples taken for 240 minutes. Microdialysis vials were stored at -80°C until analysis. Each microdialysis sample was manually aspirated and prepared and analyzed on the Ultradian LCMS/MS Platform using a modified method as previously described (19). The assay precision for cortisone was 3.3% to 5.0% relative standard deviations (RSD), and the accuracy ranged from 94% to 104%. The assay precision for cortisol was 2.8% to 5.8% RSD, and the accuracy ranged from 98% to 100%. Lower limit of quantification was 69 pmol/L for both cortisol and cortisone. Because of low volumes of dialysate in some microdialysis samples, levels below 69 pmol/L have been reported but may have reduced accuracy and precision.

Assessment of genes related to adipose tissue GC action: adipose tissue biopsy

Subcutaneous adipose tissue biopsies were performed on the patient study population at baseline (on IR-HC) and the end of the 12-week treatment cycle with DR-HC. Subcutaneous adipose tissue from the abdominal wall was taken at the level of the umbilicus, approximately 4 to 7 cm lateral to the umbilicus. After local anaesthetic preparation of the area, a 14G biopsy needle was inserted and suction applied to the syringe by using a 4.5-mL vacutainer, to obtain a sufficient sample in the syringe. The collected sample was immediately snap-frozen in liquid nitrogen and stored at -80°C until analysis.

Total RNA was extracted using the Tri-Reagent protocol. RNA concentration and purity were assessed using NanoDrop Spectrophotometer technology (ND1000, Thermo Scientific, Wilmington, DE, USA). One microgram of total RNA was used for reverse transcription and diluted to a final concentration of 50 ng/ μL . Reverse transcription was carried out using TaqMan Reverse Transcription Reagents (Applied Biosystems Ltd). In this protocol, gRNA was reverse transcribed following the manufacturer's protocol. All reactions were incubated in a thermal cycler using the recommended cycling parameter: 25°C for 10 minutes, 37°C for 30 minutes, 95°C for 5 minutes, and 4°C indefinitely. The cDNA was stored at -20°C until PCR performed. For quantitative PCR amplification of cDNA, all probes and primers were supplied by Applied Biosystems/Life Technologies as expression assays (TaqMan gene expression assays, catalog number 4331182:11 β HSD1, Hs01547870_m1; 11 β HSD2, Hs00388669_m1; NR3C1, Hs00353740_m1) and used following the manufacturer's protocol. All reactions were normalized against the housekeeping genes, 18S rRNA, glyceraldehyde-3-phosphate dehydrogenase, and peptidylprolyl isomerase A (20). Expression levels were determined using the ABI PRISM 7900HT Sequence Detection System (Thermo Fisher Scientific).

Statistical Analysis

The normality of quantitative variables was tested with the Shapiro-Wilk test. The baseline characteristics of the groups were presented as mean (SD) or median (interquartile range [IQR]) as appropriate. The differences between the posttreatment and baseline data were evaluated with paired *t*-tests in a single group for quantitative variables and χ^2 for categorical variables or the appropriate nonparametric test. Subgroup analysis was done to report the significance of treatment-by-subgroup interaction.

Real-time PCR data were obtained as Ct values (Ct = cycle number at which logarithmic PCR plots cross a calculated threshold line) and used to determine ΔCt values [$\Delta\text{Ct} = (\text{Ct of the target gene}) - (\text{Ct of the reference gene})$]. All statistical analysis of real-time PCR data was performed on mean ΔCt values between different treatment groups.

Significance was defined for *P* values less than 0.05. Statistical analysis was performed using GraphPad Prism version 8.2.0 for Windows, GraphPad Software, San Diego, California, USA.

Results

The baseline characteristics of the study population and the impact of DR-HC on blood pressure, body composition, and QoL have been previously published (9). The study

population comprised 21 patients with PAI and 30 patients with SAI who completed both visit 1 and visit 2 (after 12 weeks of DR-HC). There were more female patients in the PAI group ($n = 12$, 57%) and more males in the SAI group ($n = 22$, 73%). The study patients were on a median daily dose of 20 mg (IQR 15–20 mg) of IR-HC at study entry.

Global Corticosteroid Metabolism: Urinary Steroid Excretion

Patients on IR-HC vs controls

We investigated urinary steroid excretion in a subcohort of our patient population and compared this with a healthy age-, gender-, and BMI-matched control population. A summary of patient and control characteristics with available 24-hour and diurnal (8-hourly interval) urinary steroid excretion is provided in Table 1. We observed significantly lower 24-hour excretion of androgen metabolites and all classes of steroid precursor metabolites; androgen, mineralocorticoid, and glucocorticoids, in patients with AI requiring GC replacement therapy compared with healthy controls (Fig. 2).

Patients with AI receiving IR-HC (median, 20 mg [IQR, 16.25–20 mg]) had a higher median 24-hour excretion of urinary cortisol compared with healthy controls (72.1 $\mu\text{g}/24$ hour [IQR 43.6–124.2] vs 51.9 $\mu\text{g}/24$ hour [35.5–72.3], $P = .02$), Fig. 3A. Additionally, we observed a significant correlation between the hydrocortisone dose and total 24-hour urinary GC metabolite excretion in the patient population ($r^2 = 0.27$, $P < .001$), Fig. 3B.

Within the diurnal urine excretion profiles, we observed a significant increase in the urinary excretion of the cortisol metabolite 5 α -THF (median, 403.4 [IQR, 129.6–603.6] $\mu\text{g}/8$ hours vs 196.5 [IQR, 113.7–254.1] $\mu\text{g}/8$ hours, $P = .04$) in the morning urine collection, but there was no significant increase in total urinary cortisol (F) excretion or total GC excretion across the diurnal collections in patients receiving IR-HC compared with controls. We observed a significantly lower median urinary cortisol (F) excretion (3.4 [IQR, 1.5–13.0] $\mu\text{g}/8$ hours vs 23.1 [IQR, 3.3–33.6] $\mu\text{g}/8$ hours, $P = .02$) compared with healthy controls in the nighttime collection.

When investigating the activity of key enzymes involved in steroid metabolism, we observed a significant increase in the ratio of 24-hour urinary cortisol/cortisone excretion in patients with AI compared with control population (ratio, 0.78 [IQR, 0.6–0.86] vs 0.58 [IQR, 0.5–0.64], $P < .0001$); however, there was no difference in the activity of 11 β -HSD1 as indicated by lack of significant change in the ratio of THF + 5 α -THF/THF. We also observed a significant increase in the ratio of 5 α -THF/THF in the patient population (ratio 0.57 [IQR, 0.36–0.76] vs 0.43 [IQR, 0.32–0.54], $P = .02$), reflecting an increase in 5 α R activity in patients receiving IR-HC therapy (Fig. 4).

Effect post-dual-release hydrocortisone

Following the switch from IR-HC to DR-HC therapy, there was a significant reduction in urinary cortisol excretion compared to baseline (median, 72.1 [IQR, 43.6–124.2] $\mu\text{g}/24$ hours vs 37.4 [IQR, 22.2–75.3] $\mu\text{g}/24$ hours, $P < .001$), in addition to a reduction in total GC metabolite excretion (visit 1: median, 6659 [IQR, 3358–11151] $\mu\text{g}/24$ hours; visit 2: median, 5438 [IQR, 3515–7562] $\mu\text{g}/24$ hours, $P = .015$), Fig. 5A–B.

Table 1. Demographic data for patients with adrenal insufficiency receiving IR-HC (visit 1) who underwent 24-hour urinary steroid profiling and diurnal urinary steroid profiling, and available age- and BMI- matched control data

Characteristic	Patients with AI on IR-HC (visit 1)	Control cohort with 24-h urine collections	Control cohort with diurnal urine collections
Male/female (n/n)	20/20	30/30	10/8
Age (mean, SD) (y)	46 ± 12	48 ± 12	44.9 ± 11
AI phenotype			
Primary AI (n)	21	NA	NA
Secondary AI (n)	19		
HC dosage mg/d (median, IQR)	20 (16.25-20)	NA	NA
BMI kg/m ² (median, IQR)	26.6 (24.4-30.6)	26.9 (25.1-29)	27.0 (24-30)

Abbreviations: AI, adrenal insufficiency; BMI, body mass index; IQR, interquartile range; IR-HC, immediate release hydrocortisone.




Figure 2. Steroid metabolite excretion (µg/24 hours) assessed by LC-MS/MS in healthy controls (n = 60) and patients with adrenal insufficiency receiving IR-HC (n = 40). The metabolites were divided into metabolites of androgens and precursors (blue), mineralocorticoids and precursors (green), glucocorticoid precursors (yellow), and glucocorticoids (orange). Box-and-whisker plots represent mean steroid excretion concentration and 5th and 95th percentiles. Significance = *P* value < .05 compared with healthy controls; **P* < .05; ***P* < .01; ****P* < .001; *****P* < .0001.




Figure 3. (A) 24-hour urinary excretion of cortisol in patients with adrenal insufficiency receiving IR-HC (n = 40) and healthy age- and BMI-matched control population (n = 60). (B) Correlation of 24-hour urinary excretion of total glucocorticoid (GC) metabolites with hydrocortisone dose in patients with AI. Box-and-whisker plots represent mean steroid excretion concentration and 5th and 95th percentiles. Significance = *P* value < .05.




Figure 4. Twenty-four-hour urinary steroid excretion ratios in patients with adrenal insufficiency at baseline receiving IR-HC (n = 40) and healthy age- and BMI-matched controls (n = 60). (A) (THF + 5α-THF)/THE (measure of global 11β-HSD1), (B) urinary F/E (cortisol/cortisone) excretion (measure of 11β-HSD2), and (C) 5α-THF/THF (measure of 5α reductase activity). Box-and-whisker plots represent mean steroid excretion concentration and 5th and 95th percentiles. Significance = * P value < .05, ** P value < .01.

After 12 weeks of DR-HC therapy, patients had significantly lower urinary cortisol excretion in the morning (22.0 [IQR, 12.13-43.9] μg/8 hour vs 40.6 [IQR, 20.1-69.9] μg/8 hour, $P = .002$) and evening (4.3 [IQR, 2.6-20.4] μg/8 hour vs 16.4 [IQR, 5.4-38.2] μg/8 hour, $P = .0016$) compared with IR-HC therapy but not significantly lower than the healthy control population, Fig. 5D. There was no significant change in urinary cortisol excretion overnight after 12 weeks of

DR-HC compared with baseline, however, urinary cortisol excretion was significantly lower than controls.

We observed a significant reduction in the urinary cortisol/cortisone ratio, indicating increased 11β-HSD2 activity, after 12 weeks of DR-HC compared with baseline (0.61 [IQR, 0.49-0.74] vs 0.78 [IQR, 0.6-0.86], $P < .001$), Fig. 5C. There was no significant difference in the global activity of 11β-HSD1 or global 5αR activity in patients after 12 weeks of DR-HC.

Hepatic corticosteroid metabolism (cortisol generation profile)

Serum cortisol generation profiles (serum cortisol and cortisone after 1 mg of dexamethasone ingestion) measured via LC-MS/MS were available in 22 patients (11 males) on IR-HC (visit 1) and post 12 weeks of DR-HC (visit 2) and 11 controls (5 males), who were matched by age and BMI. Given the limited number of control data available for this analysis, we did not subdivide the cohort by gender because this would reduce the power of the analysis. All patients (n = 22) and healthy controls (n = 11) suppressed their morning fasting cortisol levels to <50 nmol/L following 1 mg dexamethasone ingestion the previous night. As expected (because of the preexisting AI), the mean fasting cortisol concentration level after dexamethasone suppression was significantly lower in patients with AI at baseline compared with the healthy control population (3.3 ± 7.4 vs 20.0 ± 4.9 nmol/L, $P < .0001$). Patients with AI on IR-HC reached a higher peak mean cortisol level following oral cortisone (531 ± 183 nmol/L vs 480 ± 138 nmol/L, $P = .42$) at an earlier timepoint of 60 minutes vs 120 minutes in the control population; however, this was not statistically significant, Fig. 6A. Interestingly, the healthy control patients had higher serum cortisone concentrations than patients with AI at 240 minutes after cortisone ingestion (49 ± 16 nmol/L vs 61 ± 14 nmol/L, $P = .04$), Fig. 6B.

After 12 weeks of DR-HC, there was no significant difference in the mean fasting cortisol concentrations after dexamethasone suppression (6.3 ± 9.6 nmol/L vs 3.3 ± 7.4 nmol/L, $P = .15$). The peak mean cortisol levels generated following cortisone acetate were similar at baseline and after DR-HC (531 ± 183 nmol/L vs 532 ± 189 nmol/L, $P = .9$). We assessed the ratio of serum cortisol to cortisone, a measure of hepatic 11β-HSD1 activity, in the patient population and the controls. There was no statistical difference in the ratio of serum cortisol/cortisone observed at any timepoint after 12 weeks of DR-HC, Fig. 6C.

Adipose Tissue Corticosteroid Metabolism

Subcutaneous adipose tissue microdialysis

Adipose tissue microdialysis samples were analyzed in 27 study patients with adrenal insufficiency (18 SAI, 9 PAI; 15 male, 12 female). Cortisol generation profiles (measurement of cortisol and cortisone after 1 mg of dexamethasone ingestion) were measured via LC-MS/MS on IR-HC (visit 1) and after 12 weeks of DR-HC (visit 2). There was a reduction in cortisol concentrations in the subcutaneous adipose tissue dialysate after 12 weeks' of DR-HC, with a significant reduction between timepoint 120 to 240 minutes after oral cortisone ingestion (17.1 ± 9.1 nmol/L vs 11.4 ± 3.0 nmol/L, $P = .007$), Fig. 7C.

Subcutaneous adipose tissue gene expression

Subcutaneous adipose tissue biopsies were available for analysis in 10 patients before and after 12 weeks of DR-HC.




Figure 5. The 24-hour urinary excretion of (A) cortisol (F), (B) total glucocorticoid (GC) metabolites, (C) urinary cortisol/cortisone (F/E) ratio, and (D) diurnal 8-hour urinary excretion of cortisol, in patients with AI on IR-HC (visit 1), 12 weeks after DR-HC (visit 2), and healthy age- and BMI-matched controls. 5 α -THF, 5 α tetrahydrocortisol; DR-HC, dual-release hydrocortisone; E, cortisone; F, cortisol; GC, glucocorticoids; THE, tetrahydrocortisone. Box-and-whisker plots represent mean steroid excretion concentration and 5th and 95th percentiles. Significance = P value < .05; ns, not significant; * P < .05; ** P < .01; *** P < .001.

We did not have subcutaneous adipose tissue available in the control population. Expression of 11 β -HSD1 (HSD11B1) was significantly lower in subcutaneous adipose tissue after DR-HC compared with IR-HC (mean Δ Ct before and after DR-HC, 5.8 ± 1.0 vs 4.4 ± 1.8 , respectively, $P = .03$), whereas there was a significant increase in the expression of the glucocorticoid receptor (GR) gene, NRC31 (mean Δ Ct before and after DR-HC, 5.9 ± 1.0 vs 7.1 ± 1.1 , respectively, $P = .02$), Fig. 8.

Discussion

This prospective study characterizes, for the first time, global, liver, and adipose tissue-specific corticosteroid metabolism in patients with primary and secondary adrenal insufficiency. We also report the differential impact of immediate-release hydrocortisone therapy and treatment with dual-release HC (Plenadren®) on steroid metabolism in AI.

There is a paucity of data investigating tissue corticosteroid metabolism in patients with AI receiving GC replacement therapy. In a cross-sectional study of patients with SAI, Sherlock et al demonstrated significant abnormalities in markers of corticosteroid metabolism in patients receiving

IR-HC (21). A recently published study by Espiard and colleagues (22) focused on patients with primary adrenal insufficiency receiving DR-HC and observed significant alterations in the urinary steroid metabolome during DR-HC therapy compared with a 3-times-daily regimen of IR-HC. However, to our knowledge, no previous study has concurrently assessed both global and tissue-specific glucocorticoid metabolism as this study has done.

In our study, there was a significant difference in the 24-hour urinary steroid profile in patients with AI receiving IR-HC compared with healthy gender-, age-, and BMI-matched controls. We observed a significant difference in the 24-hour excretion of urinary cortisol in patients receiving IR-HC compared with controls, supporting data published in patients with SAI (21); however, there was no significant difference between total GC metabolite excretion between patients with AI and the control group. Espiard et al, using gas chromatography-MS measurement of 24-hour urinary steroids, reported significantly increased urinary GC metabolites compared with a healthy matched control population (22). This is in contrast to the findings in our study, which is potentially explained by the physiological daily dose of HC our study population received (median,




Figure 6. Cortisol generation time curves. Analysis of serum (A) cortisol, (B) cortisone, and (C) cortisol/cortisone (F/E) ratio after 25 mg of cortisone acetate, in patients with adrenal insufficiency receiving IR-HC (visit 1, $n = 22$) and after 12 weeks of DR-HC (visit 2, $n = 22$) and in healthy matched controls ($n = 11$). Data are expressed in mean (standard error of the mean).

20 mg [IQR, 16.25–20]) compared with the study by Espiard et al where the study population received a clearly supraphysiologic mean daily HC dose of 30.1 mg (± 5.5) (23). We did observe a significant positive correlation between HC dose and total urinary GC metabolite excretion in our patients, highlighting the importance of the daily HC dose in patients with AI with regard to overall tissue exposure to GC.

Following 12 weeks of dual-release hydrocortisone, we observed a significant reduction in 24-hour urinary cortisol and total GC metabolite excretion compared with patients receiving IR-HC; by the end of 12 weeks, this excretion rate was not different from healthy controls. A reduction in urinary cortisol after 12 weeks of DR-HC suggests reduced global corticosteroid exposure. This is likely to result in metabolic benefits, given the observation in the study by Sherlock et al that urinary cortisol metabolites correlate positively with central-to-thigh fat ratio, as assessed by dual energy X-ray absorptiometry in patients receiving HC (21). This reduction may account for the favorable changes in metabolic and QoL outcomes we observed in our study population (9).

Immediate-release HC results in peaks and troughs in serum cortisol over the day (14), which may not be reflected in a 24-hour urine collection because this provides a global assessment of urinary steroid excretion. Therefore, we assessed diurnal variation in urinary steroid excretion by urine

collections performed in 8-hour intervals. In patients receiving DR-HC, there was a significant reduction in urinary cortisol in the morning and evening compared with IR-HC, to concentrations like those seen in the control group. Several studies have explored different HC regimes in patients with AI to identify the best strategy to replicate the distinct diurnal rhythm of cortisol secretion; however, those regimes inevitably result in steroid overreplacement or underreplacement across the 24-hour period (14, 24–27). Furthermore, even in healthy populations, high evening cortisol levels are associated with an increased risk of future glucose disturbance (28–30), a higher prevalence of vertebral fracture (31), and adverse effects on recognition memory (32). Plat et al showed that in a group of healthy males, administration of 50 mg of hydrocortisone at 5 PM produced a more pronounced elevation in glucose levels and serum insulin and reduced insulin clearance, than when given at 5 AM (ie, near the peak of the normal circadian rhythm of the hypothalamic–pituitary–adrenal axis) (33). An elevation in nadir evening cortisol concentrations, as can occur in patients on thrice daily HC regimes, could be associated with disturbances in glucose tolerance (34). DR-HC therapy aims to avoid the peaks and troughs associated with immediate-release HC, potentially accounting for the favorable metabolic outcomes seen in our study patients and previous studies (9, 34).




Figure 7. Microdialysis subcutaneous adipose tissue analysis in patients with AI receiving IR-HC (visit 1) and after 12 weeks of DR-HC (visit 2). (A) Microdialysis subcutaneous adipose tissue generation of cortisol after ingestion of 25 mg oral cortisone acetate. (B) Area under the curve (AUC) analysis of subcutaneous adipose tissue cortisol generation at time 0 to 90 minutes after cortisone acetate. (C) Time 120–240 minutes after cortisone acetate. Data are expressed in mean (standard error of the mean). Significance = P value < .05; ns, not significant; * P < .05; ** P < .01; *** P < .001. No statistically significant difference between individual cortisol concentrations at each timepoint from visit 1 and visit 2 (A); however, there was a difference in AUC cortisol 120–240 minutes after ingestion of cortisone acetate (C).

11 β -HSD isozymes modify the local action of glucocorticoids, whereas the A-ring reductases (5 α - and 5 β -reductase) inactivate cortisol (in conjunction with 3 β -hydroxysteroid dehydrogenase) to its tetrahydro-metabolites (5 α -THF and THE) (35). We observed a significant elevation in the ratio of 24-hour urinary cortisol/cortisone excretion in patients receiving immediate-release HC compared with controls, suggesting reduced 11 β -HSD2 activity. After 12 weeks of DR-HC, there was a significant reduction in urinary cortisol/cortisone excretion, reflecting increased 11 β -HSD2 activity, and thereby a reduction in tissue exposure to cortisol by inactivation to cortisone. Within the diurnal urine collections, we observed increased 11 β -HSD2 activity (decreased urinary cortisol/cortisone ratio) across all collections, most significant in the evening collection (4:00 PM–midnight) potentially offering a protective effect for the tissue, at a time at which physiological cortisol exposure is at its lowest (36).

The activity of the 11 β -HSD2 in the kidney, protecting the mineralocorticoid receptor from inappropriate activation by cortisol, plays an important role in the maintenance of blood pressure control. The clinical importance of 11 β -HSD2 is highlighted by congenital or acquired deficiencies in 11 β -HSD2, which result in the syndrome of apparent mineralocorticoid excess presenting with classical features of hyperaldosteronism, including salt retention, potassium wasting, and hypertension (37–41). It has also been proposed that reduced activity of 11 β -HSD2 could contribute to the pathogenesis of human essential hypertension, especially in its salt-sensitive form (42, 43). Previous clinical studies have shown increased urinary free cortisol/urinary free cortisone

ratios, consistent with reduced 11 β -HSD2 activity, in hypertensive patients (42, 44–46). The observation of decreased urinary cortisol/cortisone ratio in our study population may, therefore, in part explain the observed reduction in blood pressure after 12 weeks of DR-HC in our study population (9). The alteration in the urinary free cortisol/urinary free cortisone ratio may also reflect the reduction in substrate (cortisol) delivery to 11 β -HSD2, which would result in a reduction in its activity; however, delineating these 2 hypotheses is beyond the scope of this study.

We also observed a significant increase in the ratio of 5 α -THF/THF in the patient population at baseline, which infers an increase in 5 α R activity. Studies have shown enhanced 5 α R activity to be associated with obesity (47) and type 2 diabetes (48), with weight loss resulting in reduced 5 α R activity and improvement in insulin sensitivity (49). Patients with polycystic ovary syndrome also exhibit alteration in 5 α R, with increased 5 α R activity correlating positively with markers of insulin resistance (50). Therefore, the observed alteration in cortisol A-ring reduction results in increased cortisol tissue exposure with potentially negative implications in the development of an adverse metabolic phenotype in patients receiving hydrocortisone replacement therapy.

The liver is the site of highest 11 β -HSD1 expression, and immunohistochemistry studies have revealed that 11 β -HSD1 expression in the human liver is localized centripetally with maximum expression around the central vein (13). Previous clinical studies have shown that after an oral dose of cortisone acetate, cortisol appears rapidly in the peripheral circulation (51, 52), in keeping with first-pass hepatic metabolism and




Figure 8. mRNA expression of HSD11B1 and glucocorticoid receptor (GR, NR3C1) from subcutaneous adipose tissue in patients receiving IR-HC (visit 1) and after 12 weeks of DR-HC (visit 2). Data expressed in arbitrary units (AUs) and as mean Δ Ct \pm standard error of the mean, significance = $P < .05$.

localization of the oxoreductase isozyme, 11 β -HSD1, to hepatocytes around the central vein (13). In our study, patients with AI receiving IR-HC had higher peak cortisol concentrations generated at an earlier timepoint compared with the control population after cortisone ingestion. This observation may reflect a difference in hepatic 11 β -HSD1 activity between patients receiving chronic daily GC therapy and controls. However, we did not observe a significant difference in the ratio of serum cortisol/cortisone, reflective of hepatic 11 β -HSD1 activity.

By contrast, we observed a reduction in the expression of 11 β -HSD1 in subcutaneous adipose tissue after 12 weeks of DR-HC. Furthermore, we have shown using adipose tissue microdialysis that adipose tissue 11 β -HSD1 activity was reduced after 12 weeks of DR-HC. Bujalska et al (53), first proposed that excessive activity of 11 β -HSD1 within visceral adipose tissue could lead to increased adipose tissue concentrations of GCs and “Cushing disease of the omentum.” Subsequently, many studies have investigated whether 11 β -HSD1 expression and activity in human adipose tissue are associated with obesity and insulin resistance (54–59). Most cross-sectional studies have suggested that adipose tissue 11 β -HSD1 expression is increased in obesity and dysglycemia in parallel with decreased hepatic activity (17, 60). Furthermore, studies investigating the effects of endogenous GC excess or Cushing syndrome have shown that adipose-specific 11 β -HSD1 knock-out mice were protected from hepatic steatosis and circulating fatty acid excess (10). Therefore, cortisol can increase expression of 11 β -HSD1 contributing to a “feed-forward loop” that might fuel adverse metabolic features (ie, cortisol increasing 11 β -HSD1 expression generating more cortisol that further increases expression within the tissue). The reduction in 11 β -HSD1 expression in subcutaneous adipose tissue, as seen in our study population, may potentially disrupt the feed-forward loop. Additionally, the observation of reduced urinary cortisol excretion after DR-HC may have an additional impact to lower 11 β -HSD1 expression, as observed in our adipose tissue biopsies.

We observed a significant increase in the expression of the NR3C1 gene encoding the GR in subcutaneous adipose tissue after DR-HC. Cortisol regenerated by 11 β -HSD1 binds to the GR within the cytoplasm and is then translocated to the nucleus, where it regulates the transcription of target genes, including those involved in inflammation (61). The GR has

also been shown to transcriptionally activate 11 β -HSD1, further amplifying GC action (62). Therefore, the observation of increased GR expression in adipose tissue in our patients after 12 weeks of DR-HC may be compensatory to the reduction in the expression and activity of 11 β -HSD1. Several human studies have examined the association between adipose tissue GR mRNA levels and features of the metabolic syndrome and have shown no association (63) or, in fact, a negative correlation with the level of adiposity (55, 64, 65) and insulin resistance (55, 65, 66).

Our study is not without limitations. The study patients were not blinded to the treatment (for safety purposes). Our study population was switched from their IR-HC regime to the daily dose equivalent of DR-HC. Pharmacokinetic studies of DR-HC have shown that there may be an overall 24-hour reduction in cortisol exposure of approximately 20%, compared with an equivalent daily dose of thrice daily immediate-release hydrocortisone (23, 67). The lower GC exposure over 12 weeks could be a factor in altering expression of key enzymes in cortisol metabolism but these changes may also be related to the more physiological cortisol concentration throughout the day (see Fig. 5). Furthermore, our previous study reported improved QoL in the patient population with DR-HC; therefore, our study patients were not clinically hypoadrenal (9). It is difficult to decipher the relative contribution of weight loss and improved metabolic health on the outcomes reported in this study because it is well-recognized that weight loss does have an impact on both hepatic and adipose tissue cortisol metabolism and 11 β -HSD1 activity (17, 49). However, this is the first study to comprehensively assess the effect of DR-HC on tissue cortisol metabolism (in multiple tissues), and this potential confounder needs to be further elucidated in future studies. Because of the intensive nature of the in vivo study protocol, a healthy control population was challenging to recruit; therefore, the size and clinical characteristics of the control groups for each experiment did differ. However a primary focus of the study was to assess the effect of DR-HC in the individual patient with the same genetic and physiological profile (ie, the patients themselves acting as a control group). Finally, we did not address racial differences in cortisol metabolism within our dataset as our study population were all Irish Caucasian.

In conclusion, this study demonstrates abnormalities in corticosteroid metabolism in patients with primary and

secondary adrenal insufficiency receiving IR-HC, resulting in increased adipose tissue GC exposure. This dysregulation is ameliorated after 12 weeks of DR-HC treatment. These alterations represent a potential mechanism underlying beneficial metabolic effects of more physiologic GC replacement regimens.

Acknowledgments

The authors thank all the study participants who kindly volunteered to participate in this study.

Funding

R.D. is funded by the Irish Research Council, The Meath Foundation, and The Irish Endocrine Society. M.S. has received funding for this Investigator-Initiated Study from Shire (IE). The funders of the study had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit for publication. The corresponding author had full access to all the data in the study and had the final responsibility for the decision to submit for publication.

Disclosures

P.S. is the Editor-in-Chief of *The Journal of Clinical Endocrinology & Metabolism*.

Data Availability Statement

Some or all datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

References

- Bensing S, Brandt L, Tabaroj F, *et al*. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. *Clin Endocrinol (Oxf)*. 2008;69(5):697-704.
- Berghthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G. Premature mortality in patients with Addison's disease: a population-based study. *J Clin Endocrinol Metab*. 2006;91(12):4849-4853.
- Sherlock M, Reulen RC, Alonso AA, *et al*. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. *J Clin Endocrinol Metab*. 2009;94(11):4216-4223.
- Filipsson H, Monson JP, Koltowska-Haggstrom M, Mattsson A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. *J Clin Endocrinol Metab*. 2006;91(10):3954-3961.
- Giordano R, Marzotti S, Balbo M, *et al*. Metabolic and cardiovascular profile in patients with Addison's disease under conventional glucocorticoid replacement. *J Endocrinol Invest*. 2009;32(11):917-923.
- Johannsson G, Ragnarsson O. Cardiovascular and metabolic impact of glucocorticoid replacement therapy. *Front Horm Res*. 2014;43:33-44.
- Ross IL, Berghthorsdottir R, Levitt N, *et al*. Cardiovascular risk factors in patients with Addison's disease: a comparative study of South African and Swedish patients. *PLoS One*. 2014;9(3):e90768.
- Lonn L, Kvist H, Grangard U, Bengtsson BA, Sjostrom L. CT-determined body composition changes with recombinant human growth hormone treatment to adults with growth hormone deficiency. *Basic Life Sci*. 1993;60:229-231.
- Dineen R, Martin-Grace J, Ahmed KMS, *et al*. Cardiometabolic and psychological effects of dual-release hydrocortisone: a cross-over study. *Eur J Endocrinol*. 2021;184(2):253-265.
- Morgan SA, McCabe EL, Gathercole LL, *et al*. 11beta-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. *Proc Natl Acad Sci U S A*. 2014;111(24):E2482-E2491.
- Tomlinson JW, Walker EA, Bujalska IJ, *et al*. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. *Endocr Rev*. 2004;25(5):831-866.
- Storbeck KH, Schiffer L, Baranowski ES, *et al*. Steroid metabolome analysis in disorders of adrenal steroid biosynthesis and metabolism. *Endocr Rev*. 2019;40(6):1605-1625.
- Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, Stewart PM. Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. *J Clin Endocrinol Metab*. 1998;83(4):1325-1335.
- Behan LA, Rogers B, Hannon MJ, *et al*. Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients. *Clin Endocrinol (Oxf)*. 2011;75(4):505-513.
- Sagmeister MS, Taylor AE, Fenton A, *et al*. Glucocorticoid activation by 11beta-hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: a cross-sectional study. *Clin Endocrinol (Oxf)*. 2019;90(1):241-249.
- Tomlinson JW, Sherlock M, Hughes B, *et al*. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. *J Clin Endocrinol Metab*. 2007;92(3):857-864.
- Woods CP, Corrigan M, Gathercole L, *et al*. Tissue specific regulation of glucocorticoids in severe obesity and the response to significant weight loss following bariatric surgery (BARICORT). *J Clin Endocrinol Metab*. 2015;100(4):1434-1444.
- Owen LJ, Adaway JE, Davies S, *et al*. Development of a rapid assay for the analysis of serum cortisol and its implementation into a routine service laboratory. *Ann Clin Biochem*. 2013;50(4):345-352.
- Methlie P, Hustad SS, Kellmann R, *et al*. Multistep LC-MS/MS assay for glucocorticoids and androgens, and its application in Addison's disease. *Endocr Connect*. 2013;2(3):125-136.
- Neville MJ, Collins JM, Gloyn AL, McCarthy MI, Karpe F. Comprehensive human adipose tissue mRNA and microRNA endogenous control selection for quantitative real-time-PCR normalization. *Obesity (Silver Spring)*. 2011;19(4):888-892.
- Sherlock M, Behan LA, Hannon MJ, *et al*. The modulation of corticosteroid metabolism by hydrocortisone therapy in patients with hypopituitarism increases tissue glucocorticoid exposure. *Eur J Endocrinol*. 2015;173(5):583-593.
- Espiard S, McQueen J, Sherlock M, *et al*. Improved urinary cortisol metabolome in Addison's disease: a prospective trial of dual-release hydrocortisone. *J Clin Endocrinol Metab*. 2020;106(3):814-825.
- Johannsson G, Nilsson AG, Berghthorsdottir R, *et al*. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. *J Clin Endocrinol Metab*. 2012;97(2):473-481.
- Groves RW, Toms GC, Houghton BJ, Monson JP. Corticosteroid replacement therapy: twice or thrice daily? *J R Soc Med*. 1988;81(9):514-516.
- Howlett TA. An assessment of optimal hydrocortisone replacement therapy. *Clin Endocrinol (Oxf)*. 1997;46(3):263-268.
- Mah PM, Jenkins RC, Rostami-Hodjegan A, *et al*. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. *Clin Endocrinol*. 2004;61(3):367-375.
- Peacey SR, Guo CY, Robinson AM, *et al*. Glucocorticoid replacement therapy: are patients over treated and does it matter? *Clin Endocrinol*. 1997;46(3):255-261.
- Hackett RA, Kivimaki M, Kumari M, Steptoe A. Diurnal cortisol patterns, future diabetes, and impaired glucose metabolism in the

- Whitehall II cohort study. *J Clin Endocrinol Metab.* 2016;101(2):619-625.
29. Hackett RA, Steptoe A, Kumari M. Association of diurnal patterns in salivary cortisol with type 2 diabetes in the Whitehall II study. *J Clin Endocrinol Metab.* 2014;99(12):4625-4631.
 30. Lederbogen F, Hummel J, Fademrecht C, et al. Flattened circadian cortisol rhythm in type 2 diabetes. *Exp Clin Endocrinol Diabetes.* 2011;119(9):573-575.
 31. Gonzalez Rodriguez E, Lamy O, Stoll D, et al. High evening cortisol level is associated with low TBS and increased prevalent vertebral fractures: OsteoLaus study. *J Clin Endocrinol Metab.* 2017;102(7):2628-2636.
 32. Gilpin H, Whitcomb D, Cho K. Atypical evening cortisol profile induces visual recognition memory deficit in healthy human subjects. *Mol Brain.* 2008;1(1):4.
 33. Plat L, Leproult R, L'Hermite-Baleriaux M, et al. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. *J Clin Endocrinol Metab.* 1999;84(9):3082-3092.
 34. Johannsson G, Skrtic S, Lennernas H, Quinkler M, Stewart PM. Improving outcomes in patients with adrenal insufficiency: a review of current and future treatments. *Curr Med Res Opin.* 2014;30(9):1833-1847.
 35. Dineen R, Stewart PM, Sherlock M. Factors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy. *Clin Endocrinol (Oxf).* 2019;90(1):3-14.
 36. Lightman SL, Birnie MT, Conway-Campbell BL. Dynamics of ACTH and cortisol secretion and implications for disease. *Endocr Rev.* 2020;41(3):bnaa002.
 37. Hunter RW, Bailey MA. Glucocorticoids and 11beta-hydroxysteroid dehydrogenases: mechanisms for hypertension. *Curr Opin Pharmacol.* 2015;21:105-114.
 38. Stewart PM, Edwards CR. The cortisol-cortisone shuttle and hypertension. *J Steroid Biochem Mol Biol.* 1991;40(4-6):501-509.
 39. Farese RVJ, Biglieri EG, Shackleton CH, Irony I, Gomez-Fontes R. Licorice-induced hypermineralocorticoidism. *N Engl J Med.* 1991;325(17):1223-1227.
 40. Monder C, Stewart PM, Lakshmi V, Valentino R, Burt D, Edwards CR. Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. *Endocrinology.* 1989;125(2):1046-1053.
 41. Whorwood CB, Sheppard MC, Stewart PM. Licorice inhibits 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. *Endocrinology.* 1993;132(6):2287-2292.
 42. Ferrari P, Krozowski Z. Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. *Kidney Int.* 2000;57(4):1374-1381.
 43. Bocchi B, Kenouch S, Lamarre-Cliche M, et al. Impaired 11-beta hydroxysteroid dehydrogenase type 2 activity in sweat gland ducts in human essential hypertension. *Hypertension.* 2004;43(4):803-808.
 44. Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R. Mildly raised corticosterone excretion rates in patients with essential hypertension. *J Hum Hypertens.* 1995;9(6):391-393.
 45. Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R. Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension. *Hypertension.* 1995;25(1):67-70.
 46. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. *Cell.* 2001;104(4):545-556.
 47. Andrew R, Phillips DI, Walker BR. Obesity and gender influence cortisol secretion and metabolism in man. *J Clin Endocrinol Metab.* 1998;83(5):1806-1809.
 48. Andrews RC, Herlihy O, Livingstone DE, Andrew R, Walker BR. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. *J Clin Endocrinol Metab.* 2002;87(12):5587-5593.
 49. Tomlinson JW, Finney J, Hughes BA, Hughes SV, Stewart PM. Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss. *Diabetes.* 2008;57(6):1536-1543.
 50. Tsilchorozidou T, Honour JW, Conway GS. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. *J Clin Endocrinol Metab.* 2003;88(12):5907-5913.
 51. Stewart PM, Wallace AM, Atherden SM, Shearing CH, Edwards CR. Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 11 beta-hydroxysteroid dehydrogenase activity in man. *Clin Sci (Lond).* 1990;78(1):49-54.
 52. Colburn WA, DiSanto AR, Stubbs SS, Monovich RE, DeSante KA. Pharmacokinetic interpretation of plasma cortisol and cortisone concentrations following a single oral administration of cortisone acetate to human subjects. *J Clin Pharmacol.* 1980;20(7):428-436.
 53. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? *Lancet.* 1997;349(9060):1210-1213.
 54. Engeli S, Bohnke J, Feldpausch M, et al. Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. *Obes Res.* 2004;12(1):9-17.
 55. Goedecke JH, Wake DJ, Levitt NS, et al. Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. *Clin Endocrinol (Oxf).* 2006;65(1):81-87.
 56. Kannisto K, Pietilainen KH, Ehrenborg E, et al. Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. *J Clin Endocrinol Metab.* 2004;89(9):4414-4421.
 57. Lindsay RS, Wake DJ, Nair S, et al. Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. *J Clin Endocrinol Metab.* 2003;88(6):2738-2744.
 58. Rask E, Walker BR, Soderberg S, et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. *J Clin Endocrinol Metab.* 2002;87(7):3330-3336.
 59. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. *Diabetes.* 2005;54(3):872-879.
 60. Michalaki M, Kyriazopoulou V, Antonacopoulou A, et al. The expression of omental 11beta-HSD1 is not increased in severely obese women with metabolic syndrome. *Obes Facts.* 2012;5(1):104-111.
 61. Staab CA, Maser E. 11beta-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation. *J Steroid Biochem Mol Biol.* 2010;119(1-2):56-72.
 62. Sai S, Esteves CL, Kelly V, et al. Glucocorticoid regulation of the promoter of 11beta-hydroxysteroid dehydrogenase type 1 is indirect and requires CCAAT/enhancer-binding protein-beta. *Mol Endocrinol.* 2008;22(9):2049-2060.
 63. Wake DJ, Rask E, Livingstone DE, Soderberg S, Olsson T, Walker BR. Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. *J Clin Endocrinol Metab.* 2003;88(8):3983-3988.
 64. Boullu-Ciocca S, Paulmyer-Lacroix O, Fina F, et al. Expression of the mRNAs coding for the glucocorticoid receptor isoforms in obesity. *Obes Res.* 2003;11(8):925-929.
 65. Michailidou Z, Jensen MD, Dumesic DA, et al. Omental 11beta-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity. *Obesity (Silver Spring).* 2007;15(5):1155-1163.
 66. Castro RB, Longui CA, Faria CD, et al. Tissue-specific adaptive levels of glucocorticoid receptor alpha mRNA and their relationship with insulin resistance. *Genet Mol Res.* 2012;11(4):3975-3987.
 67. Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. *Eur J Endocrinol.* 2009;161(1):119-130.